IL-23 Inhibitors
IL-23 inhibitors block interleukin-23, a cytokine that sustains the inflammatory T-cells behind psoriasis and inflammatory bowel disease. Targeting IL-23 specifically — rather than the broader immune suppression of older drugs — has produced some of the highest skin-clearance rates ever seen in psoriasis, with dosing as infrequent as every 12 weeks. Ustekinumab, the oldest of the group, blocks IL-12 as well as IL-23.
4 IL-23 Inhibitors in this directory
Compare IL-23 Inhibitors side by side
Browse other drug classes
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 11 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.